Navigation Links
deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business
Date:10/15/2008

REYKJAVIK, Iceland, Oct. 15 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that the company is carrying out a review of its long-term business strategy. Over the past few years deCODE has utilized its capabilities in medicinal chemistry, structural biology and human genetics to develop product and intellectual property portfolios in both therapeutics and DNA-based diagnostics. The goal of this strategic review is to optimize the value of these assets for its shareholders by sharpening the focus of its business, selling non-core assets, securing strategic partnerships, and utilizing the resources generated to underpin product development and marketing efforts in its core business. The company has engaged the Stanford Group Company to assist in evaluating deCODE's strategic alternatives and in executing swiftly on the results of this review through the identification of buyers and partners for non-core business units, programs and intellectual property. deCODE plans to provide an update on this process in its third quarter financial results conference call to be webcast live on November 6.

deCODE also announced that in order to provide more time for the completion of this review and the execution of alternatives including the sale of assets, it has elected to utilize a 30-day grace period for the scheduled October 15 interest payment on its outstanding 3.5% Senior Convertible Notes due 2011.

"We are in the process of creating a smaller, leaner deCODE that will devote its efforts and resources to one line of business. We have created a unique and growing portfolio of intellectual property, as well as a range of products and programs in both our drug development and diagnostics work, and are engaged in discussions with potential partners and purchasers for various programs and business units. We have engaged Stanford Group Company to assist us in in this task, with the aim of finding the best means of advancing the interests of our investors and realizing the potential of deCODE's assets and capabilities," said Kari Stefansson, CEO of deCODE.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics and its capabilities in chemistry and structural biology to the development of drugs and diagnostics for common diseases. deCODE's therapeutics programs include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM) for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Edward Farmer Joy Bessenger Gisli Arnason

+354 570 2819 +1 212 481 3891 +354 570 1825

edward.farmer@decode.is joy.bessenger@decode.is gisli.arnason@decode.is


'/>"/>
SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer
2. Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens
3. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
4. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
5. Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009
6. Herley Industries, Inc. Engages Jefferies Quarterdeck to Explore Strategic Alternatives
7. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
8. Marex Group Forms Business Development Department and Promotes Three Strategic Employees
9. Covance and Lilly Enter Into a Strategic R&D Collaboration
10. U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group
11. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 17, 2017 , ... While EHR data has revolutionized the ... innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on field ... a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue Cycle Solutions (MAP ... has been promoted to Chief Executive Officer. , The need for maximizing ... shift that demands the transition from pay-for-service to pay-for-performance models. By delivering efficient ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... Top neuroendocrine ... International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. ... (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 faculty ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children ... development. ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An ... , ACE.P will address what has been identified as a critical gap in preparing ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Newly published research from ... Institute emphasizes the role a private retailer can play ... The study, published online today in the American ... decision to remove tobacco from all CVS Pharmacy stores ... settings with an even greater impact on those who ...
(Date:2/16/2017)... Summary Provides understanding and access to the allergy partnering ... ... Global Allergy Partnering Terms and Agreements since 2010 report provides understanding ... world,s leading healthcare companies. - Trends in partnering ... by company A-Z, industry sector, stage of development, technology type ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Application, Cancer Type, Technology - Forecast to 2025" report to ... ... at a CAGR of around 28.6% over the next decade to ... of the prominent trends that the market is witnessing include increasing ...
Breaking Medicine Technology: